Literature DB >> 10644711

Membrane localization of TRAF 3 enables JNK activation.

H Dadgostar1, G Cheng.   

Abstract

Members of the tumor necrosis factor receptor family as well as other receptors achieve their diverse biological effects through the activation of intracellular signals including the c-Jun N-terminal kinase (JNK) pathway. Such signals are believed to be delivered through mediators known as TNF receptor-associated factors (TRAFs). Although the N-terminal zinc finger region of TRAFs has been shown to be essential for downstream signaling, there is no indication yet as to the nature of its role or of the factors that distinguish the N terminus of TRAF 3, which does not activate JNK in the systems examined thus far, from those of other TRAFs, which do activate this pathway. In the present study, it is shown that, among the known TRAFs, localization to the insoluble cell pellet fraction consistently correlates with JNK activation and that both characteristics map to the TRAF N terminus. Furthermore, it is demonstrated that forced localization of TRAF 3 to the cell membrane is sufficient to convert this molecule into an activator of JNK. This suggests that one of the roles of the TRAF N terminus may be to participate in interactions that promote the recruitment of TRAFs to the membrane and that this localization effect plays an important role in TRAF-mediated JNK activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644711     DOI: 10.1074/jbc.275.4.2539

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex.

Authors:  A Kaykas; K Worringer; B Sugden
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

2.  Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB.

Authors:  Hasem Habelhah; Shoichi Takahashi; Ssang-Goo Cho; Takayuki Kadoya; Toshiki Watanabe; Ze'ev Ronai
Journal:  EMBO J       Date:  2004-01-08       Impact factor: 11.598

3.  TRAF6 is autoinhibited by an intramolecular interaction which is counteracted by trans-ubiquitination.

Authors:  Kent Z Q Wang; Deborah L Galson; Philip E Auron
Journal:  J Cell Biochem       Date:  2010-06-01       Impact factor: 4.429

4.  TRAF2 phosphorylation modulates tumor necrosis factor alpha-induced gene expression and cell resistance to apoptosis.

Authors:  Ken Blackwell; Laiqun Zhang; Gregory S Thomas; Shujie Sun; Hiroyasu Nakano; Hasem Habelhah
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

5.  Role of NF kappa B activator Act1 in CD40-mediated signaling in epithelial cells.

Authors:  Youcun Qian; Zhendong Zhao; Zhengfan Jiang; Xiaoxia Li
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-27       Impact factor: 11.205

6.  Discrete functions of TRAF1 and TRAF2 in Drosophila melanogaster mediated by c-Jun N-terminal kinase and NF-kappaB-dependent signaling pathways.

Authors:  Guang-Ho Cha; Kyoung Sang Cho; Jun Hee Lee; Myungjin Kim; Euysoo Kim; Jeehye Park; Sung Bae Lee; Jongkyeong Chung
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 7.  The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption.

Authors:  E M Gravallese; D L Galson; S R Goldring; P E Auron
Journal:  Arthritis Res       Date:  2000-11-02

8.  A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis.

Authors:  C J Dunnill; K Ibraheem; A Mohamed; J Southgate; N T Georgopoulos
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

9.  Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes.

Authors:  Ping Xie; Bruce S Hostager; Gail A Bishop
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

10.  TRAF4, at the Crossroad between Morphogenesis and Cancer.

Authors:  Adrien Rousseau; Marie-Christine Rio; Fabien Alpy
Journal:  Cancers (Basel)       Date:  2011-06-21       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.